Current Issue

View Larger Image

Past Issues Free Subscriptions
Sponsored
Keywords



Search Results - Cell Therapeutics
 More »

  • RuiYi Licenses mAb Development to China's Genor
    breakthrough therapeutics for the Chinese healthcare system." The agreement comes just two days after RuiYi announced it would accelerate development of a cell line for RYI-008 ...
    5-16-2013
  • Heightened Characterization of Therapeutic mAbs Using a Novel...
    Quality control and analysis of monoclonal antibody (mAb) therapeutics is required ... The complexity of cell culture systems used to produce these proteins further complicates ...
    5-15-2013
  • Sorrento, Igdrasol Secure Exclusive E.U. Distribution Rights...
    Sorrento Therapeutics and Igdrasol have acquired from Samyang Biopharmaceuticals exclusive ... including metastatic breast cancer, non-small-cell lung cancer, and ovarian cancer. ...
    5-14-2013
  • RuiYi, CMC Collaborate to Speed mAb Development
    plasmid to accelerate development of a cell line for RuiYi's monoclonal antibody ... of protein-based therapeutics for preclinical, clinical trials, and in-market production. ...
    5-14-2013
  • A First: hESCs Generated from Somatic Cells
    ... similarities and hopefully choose the best cell for future therapeutics applications," he said. "Since we have opened up the technology, hopefully the technique can be perfected. ...
    5-14-2013
  • Companion Diagnostics: 52 Pick-Up
    ... Roche (Ventana Medical Systems), Pfizer, and Cell Signaling Technology (CST) Agreement ... Metamark will also be entitled to royalties on worldwide net sales of therapeutics and any ...
    5-9-2013
  • Pharma Builds Bridges with Advocacy Groups
    Raptor kept communication lines open by furnishing the cell number of an executive willing ... Big pharmas can also learn about engagement from Acorda Therapeutics, which markets ...
    5-7-2013
  • The Tumor Microenvironment as a Drug Target, Part II
    ... epidermal growth factor receptor (EGFR) on the cell surface as well as Akt signaling. ... can complicate the challenge of developing therapeutics to target cancer pathophysiology. ...
    5-7-2013
  • Human iPSC-Derived Hepatocytes
    ... limitations from development while focusing on safer and more in vivo-stable therapeutics. ... the hepatocellular carcinoma derived HepG2 cell line does not respond to aflatoxin over ...
    5-1-2013
  • Ligand Buys Potential Milestone/Royalty Portfolio in Up To $4...
    assets, and broaden that portfolio beyond small molecule therapeutics into biologics. ... with developing high-performance mammalian cell lines for therapeutic protein production, ...
    4-30-2013
  • Detecting Acquired Drug Resistance in Cancer
    guide the use of available therapeutics, and the development of tumor drug resistance. ... heterogeneous, evolve constantly, and reflect many different cell types, clinicians say. ...
    4-29-2013
  • GEN | Biolinks
    Acucela ADial Pharmceuticals Adnexus Advanced BioHealing Advanced Cancer Therapeutics Advanced Cell Diagnostics Advanced Microscopy Group Advanced Scientifics Advaxis Advenchen ...
  • Literature Review: Which Drug Combination Will Unlock Triple...
    form of breast cancer that does not currently have any targeted therapeutics available. ... TNBC cell growth is likely not fueled by estrogen, progesterone, or Her2 (the ligands for ...
    4-25-2013
  • EpiVax and BioAtla Merge Screening Technologies
    EpiVax focuses on immunogenicity screening for protein therapeutics, immunogenicity mitigation, and T cell-driven vaccine design, using a suite of in silico tools. These tools are ...
    4-24-2013
  • Biosimilars: 10 Drugs to Watch
    ... studies as of 2012 BioXpress Therapeutics: Biosimilar in active development ... September 2008 for cancer, hematopoietic stem cell transplantation, and neutropenia Dr. ...
    4-22-2013
  • More »

    Journal Articles

  • Identification of the Chondrocyte Lineage Using Microfibril-Associated...
    Stephen Rapko, Mindy Zhang, Brenda Richards, Elizabeth Hutto, Sandra Dethlefsen, Stephen Duguay
    Tissue Engineering, Part C: Methods
    Tissue Engineering, Part C: Methods Methods for the lineage identification of cell or tissue-engineered therapeutics must provide a high degree of performance to confidently ...
  • Mesenchymal Stem Cell Therapy for Cutaneous Wounds
    Anne M. Hocking
    Advances in Wound Care
    Mesenchymal Stem Cell Therapy for Cutaneous Wounds Advances in Wound Care Background: ... used in conjunction with other therapeutics that modulate the diabetic wound environment. ...
  • Bone Tissue Engineering and Regeneration: From Discovery to the...
    Regis J. O'Keefe, Jeremy Mao
    Tissue Engineering, Part B: Reviews
    of multiple disciplines such as cell biology, stem cells, developmental and ... and strategies for translation of fundamental discoveries into clinical therapeutics.
  • Vascular Morphogenesis of Adipose-Derived Stem Cells is Mediated...
    Daphne L. Hutton, Elizabeth A. Logsdon, Erika M. Moore, Feilim Mac Gabhann, Jeffrey M. Gimble, Warren L. Grayson, Felim Mac Gabhann
    Tissue Engineering, Part A
    Tissue Engineering, Part A Adipose-derived stromal/stem cells (ASCs) are a promising cell source for vascular-based approaches to clinical therapeutics, as they have been shown to ...

GEN Webinars

View »

GEN Web Briefs

View »

GEN Poll

More » Poll Results » Archive »

Genome Sequencing and Patient Autonomy

Do you think ACMG’s recent recommendations for reporting incidental clinical sequencing results undermine patient autonomy?

Suggest a Poll